The legacy of pharmacogenetics and potential applications.
Some 40 years of pharmacogenetic research indicates that knowledge of human genetic diversity is essential to a broader understanding of variation in human drug response, and suggests that drug therapy tailored to the genetic characteristics of the individual may be a realistic goal. Aided by new technologies, molecular studies of genetic polymorphisms of many human enzymes, receptors, and other proteins indicate that only a limited number of important protein variants account for the diversity in drug response, raising the prospect that these variants may be cataloged relatively soon for many human populations. The next great challenge of pharmacogenetics is to pin down the cellular location and effect of these variant proteins on the pathways and networks that govern individual variation in responses to drugs and other exogenous chemicals. In this paper, we will discuss some the current challenges to progress in pharmacogenetics and newer strategies that might be used to improve prospects of drug design and personalized therapy.
Weber
W W
WW
University of Michigan, Ann Arbor, MI 48109-0632, USA. wwweber@umich.edu
D000818:Animals; D015195:Drug Design; D014644:Genetic Variation; D049673:History, 20th Century; D006801:Humans; D010600:Pharmacology / Q000266:history*; D011110:Polymorphism, Genetic